{"entity":{"id":"nct07710612","kind":"trial","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","aka":[],"tldr":"A phase 2 trial of osimertinib in lung cancer, run by Abbisko Therapeutics Co, Ltd, not yet recruiting.","summary":"A Phase 2 Study of ABSK043 Combined With Osimertinib is a phase 2, interventional study registered as NCT07710612 by Abbisko Therapeutics Co, Ltd, with a registry enrolment figure of 72 participants, started 2026-08-31 and due to reach its primary completion in 2029-12-31. Interventions recorded: ABSK043 in combination with Osimertinib. Conditions listed: Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive. Primary outcome: - Incidence of dose-limiting toxicity (DLT); Adverse events(AEs); Serious adverse events (SAEs). Lung eligibility wording from the registry: \"NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07710612","url":"https://clinicaltrials.gov/study/NCT07710612"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["osimertinib"],"companies":["abbisko","astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07710612","phase":"2","setting":"A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of ABSK043 Combined With Osimertinib in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Abbisko Therapeutics Co, Ltd","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07710612/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}